About our work
There is currently no cure for diabetes, which can affect major organs in the body, including the heart, blood vessels, nerves, eyes and kidneys. The UK has one of the highest rates of type 1 diabetes in the world with 400,000 people currently living with the condition.
Our diabetes research team is involved in a range of studies into both Type 1 and Type 2 diabetes.
We are currently looking for volunteers to take part in the following studies. Click on the headings below to find out more about each study and see if you might be eligible to take part and help us with our research.
A clinical trial looking at improving diabetes control following gastric band surgery is being run by researchers at Guy’s and St Thomas’. The trial is designed to mimic the effects on weight loss and diabetes control that occur after more invasive surgeries (sleeve or bypass) by adding liraglutide (a diabetes medication) after gastric band surgery.
The research involves patients injecting liraglutide or placebo for six months after having gastric band surgery. Participants will then continue to be followed up for a further six months. Patients will provide data and blood samples over seven visits (including one telephone call) for the research. The trial is taking place at a number of NHS trusts in England.
For further information on this trial, including which sites are involved, please contact DiabetesResearch@gstt.nhs.uk or telephone 020 7188 1929.
Adults with obesity are at increased risk of developing associated health complications compared to patients who are of normal weight. Liraglutide 3.0mg (Saxenda) is a drug recently approved for the treatment of obesity, which has demonstrated its safety and effectiveness. In people with obesity, the drug has been shown to improve blood pressure and diabetes control as well as to prevent diabetes development in those with prediabetes.
However, Liraglutide 3.0mg (Saxenda) is not equally effective in all people with obesity and the high cost of the medication makes it less attractive to the health service for use routinely in obesity clinics. Previous studies have shown that patients able to achieve more than 15% weight loss at one year after the treatment (‘good’ responders) will usually also achieve significant weight loss in the first months of treatment (‘early’ responders).
The aim of this study is to investigate the effectiveness and cost-effectiveness of Liraglutide 3.0mg (Saxenda) in the obesity clinic setting with a protocol for targeted use of the medication in patients who are ‘early’ and ‘good’ responders to the treatment. This approach is expected to minimise the side-effects and unnecessary exposure of those who will not achieve significant weight loss with the drug, optimise the costs of the medications and target the patients who will benefit more from its use.
Do you suffer from prediabetes, diabetes, hypertension or obstructive sleep apnoea? Do you have a BMI ≥35 kg/m2 and have you been referred to your tier 3 weight management or equivalent service? If yes then the Strive study could be for you. Your local weight management service is participating in this study, and may ask you to consider participating. Patients are unable to self-refer to this study – please discuss participation with your clinician.
For further information on this trial, please contact DiabetesResearch@gstt.nhs.uk or telephone 020 7188 1932.
Read about past studies. Please note we are no longer recruiting volunteers for these trials.
ADDRESS 2 study
The purpose of the study is to identify people newly diagnosed with Type 1 diabetes, and the brothers and sisters (siblings) of people with Type 1 diabetes, who might be interested in taking part in future diabetes research studies.
We want to collect information and blood samples from these people to understand more about the development and progression of Type 1 diabetes, and to help find suitable trials of new treatments or other studies into diabetes that they might want to take part in. When we find suitable trials or diabetes studies we will write to the eligible people to ask if they would be interested in taking part.
In Type 1 diabetes, the body’s immune system attacks its own insulin-producing beta cells in the pancreas. The beta cells are gradually damaged and eventually the body cannot make insulin. This lack of insulin can be treated effectively with insulin injections.
New treatments are being developed for Type 1 diabetes which aims to improve upon insulin given via injection. For example, new treatments have been designed to slow down or stop the body’s immune system from destroying its beta cells. We need people with diabetes to help test these treatments to find out whether they work or not.
For more information about the study, visit the ADDRESS2 study website or contact our diabetes research team at email@example.com, quoting 'Address 2'.
Before a new medication can be approved for use, it is necessary to determine whether it is safe and effective. This is done by carrying out research studies (or clinical studies).
Your kidneys have many small blood vessels. The prolonged high sugar levels in your blood, caused by Type 2 diabetes, can damage these vessels. If this happens, your kidneys cannot perform their function in cleaning your blood from waste products. The symptoms of diabetic kidney disease become apparent later when a protein called albumin is detected in the urine (this is called albuminuria).
The purpose of the study is to see if a new medicine called ASP8232 is both effective and safe as a treatment for reducing albuminuria in patients with chronic kidney disease and Type 2 diabetes mellitus. ASP8232 is a novel compound and it has not been approved yet by the Medicines And Healthcare Regulatory Agency (MHRA) in the UK.
The information collected in this study is necessary to find out whether the treatment tested is effective and safe. The information about you will be kept anonymous. Information may be used for seeking approval from the regulatory authorities to market the medicine for the treatment of chronic kidney disease as a result of Type 2 diabetes. It may also be used in reports of the study or for scientific presentations. Astellas may also use the information from this study for future medical research.
If you would like to know more about this study, please contact the Guy's and St Thomas' diabetes research team at DiabetesResearch@gstt.nhs.uk, quoting 'Album'.
The credence study is looking at an investigational medication versus placebo to see if it can slow down the progression of kidney disease in patients with Type 2 diabetes. Not everyone in the study will receive active study drug. Half of the patients will receive active study drug and the other half will receive a placebo.
An investigational agent is being evaluated in this study; the safety and efficacy of this agent has not been established.
If you would like to know more about this study, please contact the Guy's and St Thomas' diabetes research team at DiabetesResearch@gstt.nhs.uk, quoting 'Credence'.
MultiPepT1De is a research study being conducted at Guy’s Hospital. They are looking into the possibility of slowing the progression of diabetes. The approach involves giving injections under the skin of small fragments of the protein molecules found in the beta cells of the pancreas, called peptides.
It is hoped that this treatment will re-train the immune system so that it stops recognising beta cells as a target for destruction. The current study is testing the safety of a vaccine they have designed along these lines, as well as its effects on the immune system. It is a mixture of several peptides from beta cells and is called “MultiPepT1De”. The study is the first time these particular peptides have been used in humans, and this is a necessary step in the development of this type of vaccine therapy. Other peptide mixtures have been used safely in other diseases. One of the single peptides in the MultiPepT1De mixture has been used safely in another study on volunteers with type 1 diabetes.
For more information, you can visit the MultiPepT1De study website or contact the research team at firstname.lastname@example.org.
The purpose of this study is to investigate the potential beneficial effects on the kidney of a new medication for diabetes called Dapagliflozin. Dapagliflozin prevents glucose absorption in the kidney by blocking a glucose transporter called sodium-glucose transporter-2 (SGLT2). Dapagliflozin causes increased amounts of glucose being lost in the urine (glucosuria) and thereby helps lowers glucose levels in the blood. We will study the effects of Dapagliflozin in patients with Type 2 diabetes who have evidence of diabetic renal disease (diabetic nephropathy) to see if this treatment can help reduce kidney damage.
If you would like to know more about this study, please contact the Guy's and St Thomas' diabetes research team at DiabetesResearch@gstt.nhs.uk, quoting 'DEER'.
This study is being conducted to evaluate the effects of atrasentan on renal outcomes in subjects with Type 2 diabetes and nephropathy.
If you would like to know more about this study; please contact the diabetes research team at DiabetesResearch@gstt.nhs.uk, quoting 'SONAR'.